As shown in the ODYSSEY Outcomes Trial, alirocumab lowers Lp(a). FOURIER also demonstrated similar results with evolocumab. What are the implications of these findings and how do you translate the results into medical cardiology practice?

As shown in the ODYSSEY Outcomes Trial, alirocumab lowers Lp(a). FOURIER also demonstrated similar results with evolocumab. What are the implications of these findings and how do you translate the results into medical cardiology practice?

As shown in the ODYSSEY Outcomes Trial, alirocumab lowers Lp(a). FOURIER also demonstrated similar results with evolocumab. What are the implications of these findings and how do you translate the results into medical cardiology practice?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY